Trade Jazz Pharmaceuticals plc - JAZZ CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.22 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 107.35 |
| Open | 106.81 |
| 1-Year Change | -24.17% |
| Day's Range | 106.81 - 110.65 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 25, 2024 | 107.35 | 0.30 | 0.28% | 107.05 | 108.59 | 106.96 |
| Apr 24, 2024 | 108.19 | -0.26 | -0.24% | 108.45 | 109.20 | 107.43 |
| Apr 23, 2024 | 109.58 | 0.79 | 0.73% | 108.79 | 110.25 | 108.51 |
| Apr 22, 2024 | 108.68 | -1.50 | -1.36% | 110.18 | 110.21 | 108.14 |
| Apr 19, 2024 | 109.60 | 0.78 | 0.72% | 108.82 | 111.16 | 108.71 |
| Apr 18, 2024 | 108.84 | 1.79 | 1.67% | 107.05 | 109.45 | 106.10 |
| Apr 17, 2024 | 107.05 | -1.39 | -1.28% | 108.44 | 108.86 | 106.35 |
| Apr 16, 2024 | 108.44 | -1.55 | -1.41% | 109.99 | 110.60 | 108.38 |
| Apr 15, 2024 | 110.64 | 0.22 | 0.20% | 110.42 | 112.17 | 109.95 |
| Apr 12, 2024 | 110.51 | -1.78 | -1.59% | 112.29 | 112.78 | 109.94 |
| Apr 11, 2024 | 113.39 | -0.32 | -0.28% | 113.71 | 114.56 | 112.25 |
| Apr 10, 2024 | 113.93 | 1.01 | 0.89% | 112.92 | 114.24 | 112.23 |
| Apr 9, 2024 | 113.96 | -0.95 | -0.83% | 114.91 | 115.80 | 112.43 |
| Apr 8, 2024 | 114.99 | -0.96 | -0.83% | 115.95 | 116.50 | 114.45 |
| Apr 5, 2024 | 116.30 | 1.17 | 1.02% | 115.13 | 116.76 | 114.34 |
| Apr 4, 2024 | 115.01 | -1.97 | -1.68% | 116.98 | 117.61 | 114.95 |
| Apr 3, 2024 | 116.80 | -0.24 | -0.21% | 117.04 | 117.60 | 115.95 |
| Apr 2, 2024 | 117.51 | -0.48 | -0.41% | 117.99 | 119.18 | 116.64 |
| Apr 1, 2024 | 118.92 | -0.91 | -0.76% | 119.83 | 119.94 | 117.97 |
| Mar 28, 2024 | 120.18 | 0.69 | 0.58% | 119.49 | 121.37 | 118.50 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Jazz Pharma Company profile
About Jazz Pharmaceuticals PLC
Jazz Pharmaceuticals Public Limited Company is a biopharmaceutical company. The Company is focused on developing and commercializing products that address unmet medical needs. The Company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. The Company's lead marketed products include Xyrem (sodium oxybate oral solution) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze for the treatment of acute lymphoblastic leukemia (ALL), and Defitelio (defibrotide) for the treatment of severe hepatic veno-occlusive disease (VOD). The Company also commercializes Prialt, an intrathecally administered infusion of ziconotide, approved by the FDA for the management of severe chronic pain in patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies or intrathecal morphine.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Jazz Pharmaceuticals PLC revenues increased 31% to $3.09B. Net loss totaled $329.7M vs. income of $238.6M. Revenues reflect Sunosi segment increase from $28.3M to $2.34B, Zepzelca segment increase from $90.4M to $246.8M, United States segment increase of 32% to $2.82B, Europe segment increase of 31% to $230.2M. Net loss reflects Selling.
Equity composition
Common Stock $.0001 Par, 4/11, 150M auth., 40,741,809 issd. Insiders & stakeholders own 2.30%. IPO 6/1/07, 6M shares @ $18 per share by Morgan Stanley & Co. Incorporated, Lehman Brothers Inc. 5/07 Reverse stock split 1 for 11.06701. PO: 7/08, 3.8M shares.
| Industry: | Pharmaceuticals (NEC) |
Fifth Fl
Waterloo Exchange
DUBLIN
DUBLIN 4
IE
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com